aTyr Pharma, Inc. (ATYR)
| Market Cap | 93.73M |
| Revenue (ttm) | 190,000 |
| Net Income (ttm) | -75.12M |
| Shares Out | 97.99M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 932,632 |
| Open | 0.990 |
| Previous Close | 0.990 |
| Day's Range | 0.941 - 1.010 |
| 52-Week Range | 0.640 - 7.290 |
| Beta | 0.58 |
| Analysts | Hold |
| Price Target | 4.20 (+337.59%) |
| Earnings Date | Mar 17, 2026 |
About ATYR
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease rela... [Read more]
Financial Performance
In 2024, aTyr Pharma's revenue was $235,000, a decrease of -33.43% compared to the previous year's $353,000. Losses were -$64.02 million, 27.1% more than in 2023.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ATYR stock is "Hold." The 12-month stock price target is $4.2, which is an increase of 337.59% from the latest price.
News
Ethos to Participate in The Citizens Technology Conference
AUSTIN, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ: LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder ...
Ethos Technologies Inc. (LIFE) Q3 2026 Earnings Call Transcript
Ethos Technologies Inc. (LIFE) Q3 2026 Earnings Call Transcript
Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Ethos Reports 4Q and FY2025 Financial Results, Delivers 3rd consecutive year of revenue growth greater than 50%. Records full-year revenue of $387.6 Mil.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop...
Ethos to Announce Fourth Quarter 2025 Financial Results on February 25, 2026
AUSTIN, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will release its finan...
The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts.
Forgent Power Solutions, Liftoff Mobile and several consumer and biotech firms are set to go public.
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03,...
Ethos Technologies: A Surprisingly Soft Debut
Ethos Technologies: A Surprisingly Soft Debut
Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut
Ethos Technologies clinched a valuation of $1.2 billion in its Nasdaq debut on Thursday, adding to a wave of insurance companies capitalizing on buoyant investor demand.
Ethos Announces Pricing of Initial Public Offering
AUSTIN, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the pricing of its initial pub...
Ethos Technologies prices US IPO at $19/share, Bloomberg News reports
Insurance platform Ethos Technologies priced its U.S. initial public offering at $19 per share, Bloomberg News reported on Wednesday, citing a person familiar with the matter.
U.S. IPO Weekly Recap: Equipment Rental Rises While Crypto Company Crashes In 2-IPO Week
Two operating companies priced IPOs this week, along with six SPACs. Ten issuers submitted initial filings this week, with five operating companies and five SPACs. Four IPOs are currently scheduled in...
Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product
AUSTIN, Texas and DES MOINES, Iowa, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a partner...
U.S. IPO Weekly Recap: Small Issuers And SPACs Join The Pipeline In Short Holiday Week
Seven IPOs and two SPACs submitted filings this week; no pricings this week. The IPO calendar looks quiet for the week ahead, with one small issuer tentatively slated to debut. Street research is expe...
Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution
Ethos announced a partnership with Aflac to expand access to Aflac's supplemental insurance policies through Ethos's digital distribution platform.
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches tied to ...
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
LOS ANGELES , Dec. 8, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violatio...
ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired se...
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure
Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizin...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired se...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit – ATYR
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR).
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired se...